National Cancer Institute (NCI): clinical-trial pipeline
National Cancer Institute (NCI) is the sponsor of 3,554 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 780 are not yet finished and 2 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials780
Phase 2/3 and 3231
Countries76
New in 90 days2
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 1,504 |
| Phase 1 | 940 |
| Not applicable | 541 |
| Phase 1/2 | 316 |
| Phase 3 | 201 |
| Phase 2/3 | 30 |
| Early phase 1 | 19 |
| Phase 4 | 3 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 2,183 |
| Terminated | 457 |
| Active, not recruiting | 446 |
| Recruiting | 313 |
| Withdrawn or not authorised | 97 |
| Suspended or halted | 28 |
| Not yet recruiting | 21 |
| Unknown | 9 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 3,296 |
| Nephrology and urology | 442 |
| Gastroenterology and liver | 353 |
| Women's health and obstetrics | 290 |
| Rare and genetic diseases | 235 |
| Infectious disease and vaccines | 219 |
| Dermatology | 158 |
| Metabolic and endocrine (diabetes, obesity) | 133 |
| Haematology | 104 |
| Musculoskeletal | 61 |
| Respiratory | 54 |
| Cardiovascular | 37 |
Countries
| Country | Trials |
|---|---|
| United States | 3,359 |
| Canada | 279 |
| Puerto Rico | 132 |
| Australia | 59 |
| China | 33 |
| New Zealand | 25 |
| South Korea | 15 |
| Singapore | 15 |
| Israel | 14 |
| Japan | 14 |
| South Africa | 14 |
| Italy | 13 |
| Switzerland | 11 |
| Peru | 11 |
| Costa Rica | 10 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-23 | New trial posted | Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, A… |
| 2026-10-07 | New trial posted | Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizar… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients Wi… | Phase 3 | Active, not recruiting | Canada, Colombia, Spain, France +6 |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and De… | Phase 3 | Active, not recruiting | Germany, Puerto Rico, United States |
| NCT02506153 | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizum… | Phase 3 | Active, not recruiting | Canada, Ireland, United States |
| NCT05724108 | Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment… | Phase 2 | Active, not recruiting | United States |
| NCT04301076 | Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("… | Phase 1 | Recruiting | United States |
| NCT03041688 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients… | Phase 1 | Active, not recruiting | United States |
| NCT04577755 | Pomalidomide Treatment in Patients With Kaposi Sarcoma | Phase 2 | Active, not recruiting | United States |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | Phase 2 | Active, not recruiting | Canada, United States |
| NCT06102902 | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Enco… | Phase 1 | Recruiting | United States |
| NCT03919071 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Gr… | Phase 2 | Active, not recruiting | Puerto Rico, United States |
| NCT03317392 | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With… | Phase 1/2 | Active, not recruiting | United States |
| NCT03220022 | Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochlo… | Phase 1 | Active, not recruiting | United States |
| NCT00878163 | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Meta… | Phase 1 | Active, not recruiting | United States |
| NCT03965689 | Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-… | Phase 2 | Active, not recruiting | United States |
| NCT05361798 | A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combinati… | Phase 2 | Recruiting | United States |
| NCT03269578 | Sample Collection and Tracking for the Developmental Therapeutics Clinic | Not applicable | Recruiting | United States |
| NCT06222203 | Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath T… | Not applicable | Recruiting | United States |
| NCT05411081 | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2… | Phase 2 | Active, not recruiting | United States |
| NCT05136196 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Me… | Phase 2 | Recruiting | United States |
| NCT04460937 | Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Es… | Phase 1 | Active, not recruiting | United States |
| NCT03842228 | Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients… | Phase 1 | Active, not recruiting | United States |
| NCT02782949 | Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metap… | Phase 2 | Active, not recruiting | Honduras, Puerto Rico |
| NCT00977574 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carbopl… | Phase 2 | Active, not recruiting | United States |
| NCT07499128 | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event | Not applicable | Recruiting | United States |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | Not applicable | Recruiting | United States |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "National Cancer Institute (NCI) clinical trials: 780 open, 231 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/national-cancer-institute-nci/, data as of 2026-10-25.